Furthermore, the AG221-AML-005 phase 1b/2 trial compared enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed IDH2-mutated AML who were ineligible for intensive chemotherapy [53]. This evidence concerns the gene IDH2 and acute myeloid leukemia.